Edvantage Group Announces FY2023 Interim Results
HONG KONG, Apr 27, 2023 – (ACN Newswire) – Edvantage Group Holdings Limited (“Edvantage Group”…
Month: April 2023
The Executive Talk by ShareInvestor: Shrinkflex (Thailand) PCL (SET: SFT)
BANGKOK, Apr 27, 2023 – (ACN Newswire) – Mr. Sung Cheong Tsoi, Chief Executive Officer,…
The Economics Tutor (TET) Announces the Launch of Ace Your GP General Paper Tuition Programme
SINGAPORE, Apr 27, 2023 – (ACN Newswire) – The Economics Tutor (TET), a leading economics…
Fortune Brands’ Results Solidly Ahead of Expectations Amid an Anticipated Challenging Macro Environment; Increases Full-Year 2023 EPS Guidance
Highlights: Q1 2023 sales were $1.0 billion, a decrease of 9 percent versus Q1 2022…
Heliogen, Inc. Schedules Release of First Quarter 2023 Financial Results and Conference Call
PASADENA, Calif.–(BUSINESS WIRE)–Heliogen, Inc. (“Heliogen”) (NYSE: HLGN), a leading provider of AI-enabled concentrating solar energy,…
Pioneer Natural Resources Reports First Quarter 2023 Financial and Operating Results
DALLAS–(BUSINESS WIRE)–Pioneer Natural Resources Company (NYSE:PXD) (“Pioneer” or “the Company”) today reported financial and operating…
Getty Realty Corp. Announces First Quarter 2023 Results
– Increases 2023 Annual Guidance – NEW YORK–(BUSINESS WIRE)–Getty Realty Corp. (NYSE: GTY) (“Getty” or…
Acadia Healthcare Reports First Quarter 2023 Results
Company Affirms Full Year 2023 Guidance FRANKLIN, Tenn.–(BUSINESS WIRE)–Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today…
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage…
Ontrak to Report 2023 First Quarter Financial Results on May 10, 2023
HENDERSON, Nev.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled…
Wolfspeed Reports Financial Results for the Third Quarter of Fiscal Year 2023
Year-over-year Quarterly Revenue Growth of 22 Percent; Design-Ins Totaling $1.7 Billion DURHAM, N.C.–(BUSINESS WIRE)–Wolfspeed, Inc….
Align Technology Announces First Quarter 2023 Financial Results
Delivers revenue and EPS ahead of expectations, with total Invisalign® patients treated surpassing 15 million…
POSaBIT Reports Fourth Quarter and Full-Year 2022 Financial Results
POSaBIT continues streak of doubling, or nearly doubling, revenue for 5 consecutive years Raises FY…
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella, Inc. www.nexcella.com Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in…
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella, Inc. www.nexcella.com Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in…
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL)…
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL)…
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with…
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with…
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…